On February 17, 2026, HCW Biologics Inc. announced a securities purchase agreement for a follow-on public offering of approximately $1.5 million, involving 2,477,292 shares of common stock and warrants. The offering's completion is subject to stockholder approval and is aimed at reducing existing warrant exercise prices.